Cost-Effectiveness of Immunising Interventions to Reduce Respiratory Syncytial Virus Disease Burden in Infants in Australia
PharmacoEconomics · 2026
DOI: 10.1007/s40273-026-01601-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift PharmacoEconomics, 2026. Verfasst von Julian B Carlin und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC, Australia. julian…. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Antibodies, Monoclonal, Respiratory Syncytial Virus Vaccines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Immunisation Division of the Australian Government Department of Health, Disability and Ageing., University of Melbourne.
Abstract (Originalsprache)
Two immunising products are emerging to prevent the burden of respiratory syncytial virus (RSV) in infants: long-lasting monoclonal antibodies (mAbs) and maternal vaccines given during pregnancy (MV). This study assesses the potential cost-effectiveness of programs involving each product to help inform policy decisions related to their implementation in the Australian context. We developed an individual-based dynamic transmission model of RSV infection, linked to a clinical pathways model and cost-effectiveness model. We modelled key scenarios exploring varying eligibility and coverage of immunisation products for at-risk and not-at-risk populations, in addition to sensitivity analyses of immunisation characteristics, program costs and the impact of potential under-ascertainment of RSV burden. We estimated the cost-effectiveness of each program from a health system perspective, with results presented as incremental cost-effectiveness ratios in terms of cost per quality-adjusted life year gained (QALY). We found a combined program in which administration of MV during pregnancy is supplemented with a birth-dose of mAbs for newborns born without protection from MV is likely to be cost-saving, compared with the status quo of no MV or mAbs delivered. This program averted on average 41% of infant hospitalisations per year and reduced QALY losses by 33%. Programs combining infant immunisation products are likely to significantly reduce the burden of RSV disease in Australia, and be cost-saving. However, their estimated impact and cost-effectiveness is strongly dependent on key assumptions (i) the consistency and completeness of ascertainment of disease burden over time; (ii) the cost of a hospitalisation and immunising dose; (iii) the efficacy and durability of protection of the modelled products; and (iv) the timing and coverage of the immunisation delivery. Respiratory syncytial virus in infants causes significant disease burden in Australia and worldwide. Multiple immunising products are emerging—vaccines given during pregnancy to protect the newborn, and long-lasting monoclonal antibodies given to infants—but it is uncertain what the impact of these products will be at a population level. We found, using an individual-based model, that a combined program of products is likely to be cost-saving from a health system perspective.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC, Australia. julian.carlin@unimelb.edu.au.
- Department of Infectious Diseases, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC, Australia.
- Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia.
- Victorian Infectious Diseases Reference Laboratory Epidemiology Unit, Peter Doherty Institute for Infection and Immunity, The Royal Melbourne Hospital, Melbourne, VIC, Australia.
ORCID-Profile: Adrian J Marcato, Cyan Yingying Wang, Robert Moss, Kylie S Carville, Xinghui Chen, Victoria L Oliver, Violeta Spirkoska, Patricia T Campbell, David J Price, Natalie Carvalho, Jodie McVernon
Förderung
- National Immunisation Division of the Australian Government Department of Health, Disability and Ageing.
- University of Melbourne
Zitieren
APA
Carlin, J. B., Marcato, A. J., Wang, C. Y., Moss, R., Carville, K. S., Chen, X., Oliver, V. L., Spirkoska, V., Campbell, P. T., Price, D. J., Carvalho, N., & McVernon, J. (2026). Cost-Effectiveness of Immunising Interventions to Reduce Respiratory Syncytial Virus Disease Burden in Infants in Australia. PharmacoEconomics. https://doi.org/10.1007/s40273-026-01601-8
Vancouver
Carlin JB, Marcato AJ, Wang CY, Moss R, Carville KS, Chen X, et al. Cost-Effectiveness of Immunising Interventions to Reduce Respiratory Syncytial Virus Disease Burden in Infants in Australia. PharmacoEconomics. 2026. doi:10.1007/s40273-026-01601-8
BibTeX
@article{Carlin2026,
author = {Carlin, Julian B and Marcato, Adrian J and Wang, Cyan Yingying and Moss, Robert and Carville, Kylie S and Chen, Xinghui and Oliver, Victoria L and Spirkoska, Violeta and Campbell, Patricia T and Price, David J and Carvalho, Natalie and McVernon, Jodie},
title = {Cost-Effectiveness of Immunising Interventions to Reduce Respiratory Syncytial Virus Disease Burden in Infants in Australia},
journal = {PharmacoEconomics},
year = {2026},
doi = {10.1007/s40273-026-01601-8}
}
EUVIMED